Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivatrotamab (Hu3F8-BsAb) in Relapsed/Refractory Neuroblastoma and Osteosarcoma
NCT03860207Phase 2Terminated
- Sponsor
- Y-mAbs Therapeutics, Inc.
- Start
- Feb 2019
- Primary completion
- Oct 2021
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of nivatrotamab in neuroblastoma, osteosarcoma (OS) and solid tumor, sponsored by Y-mAbs Therapeutics, Inc. Primary endpoint: Dose Limiting Toxicities at 28 days. Started Feb 2019; status: terminated.
02
Drugs
nivatrotamab
03
Conditions
neuroblastomaosteosarcoma (OS)solid tumor
Beyond the preview
Go deeper on NCT03860207.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03860207.